Supporting Information for

Combination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy

Miguel A. Moreno-Gonzalez[1,4-7], Zhongchao Zhao[1,4-7], Adam A. Caparco[1,4,5,8], and Nicole F. Steinmetz[1-8*]

[1] Department of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[2] Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[3] Department of Radiology, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[4] Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[5] Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[6] Center for Engineering in Cancer, Institute of Engineering in Medicine, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[7] Moores Cancer Center, University of California, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

[8] Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States

* nsteinmetz@ucsd.edu

ORCID: https://orcid.org/0000-0002-0130-0481



Supporting Figure S1. A) Agarose gel electrophoresis of CPMV RNA staining. B) Agarose gel electrophoresis of CPMV coat protein staining. Yellow rectangles highlight the CPMV particles used for this study.



Supporting Figure S2. ID8-Defb29/Vegf-A tumor growth curves of individual groups with n = 8. A) CPMV monotherapy. B) Oxaliplatin monotherapy. C) High dose CPMV combination treatment. D) Low dose CPMV combination treatment. E) PBS.



Supporting Figure S3. B16F10 tumor growth curves of individual groups with n = 8. A) CPMV monotherapy. B) High dose OxPt monotherapy. C) High dose OxPt combination treatment. D) Low dose oxaliplatin monotherapy. E) Low dose oxaliplatin combination treatment. F) PBS.



Supporting Figure S4. Myeloid cell confocal images used for quantitative analysis.



Supporting Figure S5. NK cell confocal images used for quantitative analysis.



Supporting Figure S6. Macrophage confocal images used for quantitative analysis.



Supporting Figure S7. A.) Immunofluorescence imaging of infiltrating adaptive immune cells. Animals received one treatment on day 7 post tumor inoculation, and the tumors were collected 48 hours post treatment. The tumors were cryosectioned and stained with DAPI, anti-mouse CD4 (helper T cells), anti-mouse CD8α (cytotoxic T cells), and anti-mouse FoxP3 (regulatory T cells). The scale bar is 50μm. B.) Quantification of confocal images with 3-6 images per staining, each data point in the violin plots corresponds to the total intensity from an individual image.



Supporting Figure S8. Treg confocal images used for quantitative analysis.



Supporting Figure S9. CD4 T cell confocal images used for quantitative analysis.



Supporting Figure S10. CD8 T cell confocal images used for quantitative analysis.



Supporting Figure S11. Proliferation confocal images used for quantitative analysis.



Supporting Figure S12. Apoptotic cell confocal images used for quantitative analysis.



Supporting Figure S13. Calreticulin confocal images used for quantitative analysis.



Supporting Figure S14. HMGB1 confocal images used for quantitative analysis.